GlassScriptPhysician profile
Andrew Wiele
NPI 1447663539
$1,322.98
in general payments reported to CMS, 2019-2025
21 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.16 · 2022: $85.34 · 2023: $75.90 · 2024: $355 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intera Oncology, INC | $241.86 | 2025 | Intera |
| Novartis Pharmaceuticals Corporation | $187.30 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $133.62 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Pfizer INC. | $93.80 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $87.89 | 2022-2025 | Opdivo, Eliquis |
| Abbvie INC. | $75.96 | 2024-2025 | |
| Celgene Corporation | $52.14 | 2020-2023 | Pomalyst |
| Genentech USA, INC. | $48.92 | 2023-2025 | Tecentriq Hybreza, Polivy |
| Tempus Ai, INC | $48.78 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $48.05 | 2024-2025 | Calquence |
| Astellas Pharma US INC | $47.56 | 2022-2024 | Vyloy |
| Foundation Medicine, INC. | $39.48 | 2022-2023 | Foundationone Cdx |
| Regeneron Healthcare Solutions, INC. | $35.63 | 2024 | Libtayo |
| Dendreon Pharmaceuticals LLC | $32.77 | 2025 | Provenge |
| Shorla Oncology INC. | $28.88 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.46 | 2025 | |
| Daiichi Sankyo INC. | $27.45 | 2025 | Datroway |
| Genzyme Corporation | $24.75 | 2022 | |
| Array Biopharma INC | $20.68 | 2025 | Lorbrena |
| Ipsen Biopharmaceuticals, INC | $20.00 | 2025 | Onivyde |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wiele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.